Addressing the obesity challenge in plastic surgery - the role of liraglutide.

Abstract

literature supports the use of obesity pharmacotherapy, like liraglutide, for at least 12 months, showing a substantial percentage of weight loss. A phase 2 dose-ranging study and a series of four SCALE clinical trials provided further evidence for liraglutide’s effect on achieving and maintaining weight loss, and notable effects on improving glycemic parameters and cardiometabolic health [5].